Dendreon's Provenge Problems Reach Terminal Stage
Updated with new stock price.
SEATTLE (TheStreet) --Dendreon: Cue the fat lady.
Ouch! A painful second quarter. Yes, Dendreon announced the big expense cuts, including the shutdown of a Provenge manufacturing facility, for which Wall Street clamored. But (isn't there always a "but" with Dendreon?) Provenge sales in the quarter tanked, falling more than 2% sequentially to $80 million and instantly raising legitimate questions about slowing demand for the prostate cancer immunotherapy in the face of new competition. ...Click to view a price quote on DNDN. Click to research the Drugs industry.
Original Article: Dendreon's Provenge Problems Reach Terminal StageNEXT ARTICLE